^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Zumagev (astuprotimut-R)

    i
    Associations
    News

    Trials

    Company:
    Agenus, GSK
    Drug class:
    Immunostimulant, MAGE-A3 modulator, Tumor-associated antigen inhibitor
    Related drugs:
    Associations
    News

    Trials

    Apply
    Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma (NCT00896480)
    Phase 2
    GlaxoSmithKline
    Completed
    Last update posted :
    04/08/2021
    Initiation :
    05/19/2009
    Primary completion :
    11/03/2014
    Completion :
    11/03/2014
    ALK • CD8 • IFNG • TNFA • CD4 • MAGEA3
    |
    Zumagev (astuprotimut-R)
    A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma (PREDICT) (NCT00942162)
    Phase 2
    GlaxoSmithKline
    Completed
    Last update posted :
    12/08/2020
    Initiation :
    08/14/2009
    Primary completion :
    06/27/2012
    Completion :
    04/01/2015
    ALK • MAGEA3
    |
    Zumagev (astuprotimut-R)
    High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI (NCT01266603)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/19/2020
    Initiation :
    02/22/2011
    Primary completion :
    11/01/2018
    Completion :
    11/01/2018
    MAGEA3
    |
    Proleukin (aldesleukin) • Promune (agatolimod) • Zumagev (astuprotimut-R)
    Study to Test the Efficacy of the Vaccine GSK 249553 in Treating Non-small-cell Lung Cancer After Tumour Removal by Surgery (NCT00290355)
    Phase 2b
    GlaxoSmithKline
    Completed
    Last update posted :
    01/02/2020
    Initiation :
    05/28/2002
    Primary completion :
    07/19/2011
    Completion :
    07/19/2011
    CD8 • CD4
    |
    Zumagev (astuprotimut-R)
    Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI (NCT01425749)
    Phase 1
    Craig L Slingluff, Jr
    Completed
    Last update posted :
    04/04/2016
    Initiation :
    06/01/2011
    Primary completion :
    07/01/2013
    Completion :
    10/01/2015
    PD-L1 • BRAF • CD8 • IFNG • TNFA • CTLA4 • CD4 • IL2 • TNFRSF9 • MAGEA3
    |
    Zumagev (astuprotimut-R)